• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    CAS No. 34540-22-2 Price $40 / 20mg
    Catalog No.CFN99913Purity>=98%
    Molecular Weight975.13Type of CompoundTriterpenoids
    FormulaC48H78O20Physical DescriptionWhite powder
    Download Manual    COA    MSDSSimilar structuralComparison (Web)
    Citing Use of our Products
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
    Size /Price /Stock 10 mM * 1 mL in DMSO / $66.3 / In-stock
    Other Packaging *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
    Our products had been exported to the following research institutions and universities, And still growing.
  • Universite Libre de Bruxelles (Belgium)
  • Universidade Católica Portuguesa (Portugal)
  • Regional Crop Research Institute (Korea)
  • Medical University of South Car... (USA)
  • Sapienza University of Rome (Italy)
  • Max Rubner-Institut (MRI) (Germany)
  • Institute of Tropical Disease U... (Indonesia)
  • Centrum Menselijke Erfelijkheid (Belgium)
  • Stanford University (USA)
  • The Vancouver Prostate Centre (... (Canada)
  • Texas A&M University (USA)
  • More...
  • Package
    Featured Products
    Sanggenone K

    Catalog No: CFN92416
    CAS No: 86450-77-3
    Price: $533/5mg
    Bruceine D

    Catalog No: CFN90771
    CAS No: 21499-66-1
    Price: $258/10mg

    Catalog No: CFN90458
    CAS No: 66791-77-3
    Price: $288/20mg
    Ginsenoside Compound K

    Catalog No: CFN99756
    CAS No: 39262-14-1
    Price: $100/20mg
    Dihydrocucurbitacin B

    Catalog No: CFN92140
    CAS No: 13201-14-4
    Price: $418/5mg

    Catalog No: CFN98423
    CAS No: 3301-49-3
    Price: $238/10mg

    Catalog No: CFN97049
    CAS No: 61303-13-7
    Price: $178/20mg
    Related Screening Libraries
    Size /Price /Stock 10 mM * 100 uL in DMSO / Inquiry / In-stock
    10 mM * 1 mL in DMSO / Inquiry / In-stock
    Related Libraries
  • Anti-inflammatory Compound Library
  • Antioxidants Compound Library
  • Inhibitors Compound Library
  • Neuroprotection Compound Library
  • Cardioprotective Compound Library
  • Anti-stroke Compound Library
  • Angiogenesis Compound Library
  • Wound-healing Compound Library
  • Triterpenoids Compound Library
  • TNF-α Inhibitor Library
  • SOD Inhibitor Library
  • PKC Inhibitor Library
  • PKA Inhibitor Library
  • PGE Inhibitor Library
  • p65 Inhibitor Library
  • P450 (e.g. CYP17) Inhibitor Library
  • p38MAPK Inhibitor Library
  • NO Inhibitor Library
  • NMDAR Inhibitor Library
  • NF-kB Inhibitor Library
  • IIL Receptor Inhibitor Library
  • ERK Inhibitor Library
  • COX Inhibitor Library
  • cAMP Inhibitor Library
  • Calcium Channel Inhibitor Library
  • Biological Activity
    Description: Madecassoside is a mechanism-based inhibitor of CYP2C19 and CYP3A4, which has antioxidant, anti-inflammatory, anti-apoptosis, wound-healing, and neuroprotective activities, It may have cardioprotective effects in LPS-mediated through inhibition of ERK, p38, and NF-κB activity, it inhibited the pro-inflammatory mediators, including COX-2 expression, PGE2 production, TNF-αand IL-6 levels and the up-regulation anti-inflammatory molecule IL-10.
    Targets: COX | PGE | TNF-α | IIL Receptor | P450 (e.g. CYP17) | ERK | p38MAPK | NF-kB | cAMP | PKC | PKA | Calcium Channel | NO | p65 | NMDAR | SOD
    In vitro:
    Phytomedicine. 2009 Jun;16(6-7):538-46.
    Madecassoside attenuates inflammatory response on collagen-induced arthritis in DBA/1 mice.[Pubmed: 19135346 ]
    Madecassoside (MA), a triterpenoid product isolated from Centella asiatica, has been described to exhibit antioxidant and anti-inflammatory activities.
    The present study was undertaken to determine whether Madecassoside (MA) is efficacious against collagen-induced arthritis (CIA) in mice and its possible mechanisms. DBA/1J mice were immunized with bovine type II collagen and treated with MA (3, 10 and 30 mg/kg d, i.g.) from days 21 to 42 after immunization. Arthritis was evaluated by hind paw swelling, polyarthritis index, and histological examination. In vitro proliferation of spleen cells was examined using 3-[4,5-dimethylthylthiazol-2-yl]-2, 5-diphenyltetrazoliumbromide (MTT) assay. Plasma levels of cytokines tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-10 (IL-10) and the expression of prostaglandin E(2) (PGE(2)), cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in synovial tissues were also determined. The results showed that comparing with untreated CIA mice, treated with MA dose-dependently suppressed the clinical arthritis score and joints tissues pathological damage, reduced the proliferation of spleen cells, plasma levels of TNF-alpha and IL-6, synovial tissues PGE(2) production and COX-2 protein expression, however, the expression of COX-1 in synovial tissues did not change and the plasma levels of IL-10 were increased.
    These results suggest that MA can effectively alleviate inflammatory response on CIA, and anti-inflammatory effects of MA can be attributed, at least partially, to the inhibition of pro-inflammatory mediators, including COX-2 expression, PGE(2) production, TNF-alpha and IL-6 levels and the up-regulation anti-inflammatory molecule IL-10.
    In vivo:
    Brain Res. 2014 May 27;1565:37-47.
    Neuroprotective effects of madecassoside against focal cerebral ischemia reperfusion injury in rats.[Pubmed: 24735651]
    Madecassoside, a triterpenoid derivative isolated from Centella asiatica, exhibits anti-inflammatory and antioxidant activities.
    We investigated its neuroprotective effect against ischemia-reperfusion (I/R) injury in cerebral neurons in male Sprague-Dawley rats. Madecassoside (6, 12, or 24mg/kg, i.v.) was administered 1h after the start of reperfusion, and neurological deficit score and infarct volume were evaluated 24h later. Neuronal apoptosis was assessed by performing terminal deoxynucleotidyl transferase-mediated dUTP-nick end labeling (TUNEL) staining, and pathological brain damage was estimated by performing hematoxylin and eosin staining. Serum levels of malondialdehyde, superoxide dismutase activity, reduced glutathione levels, and nitric oxide levels were also determined. mRNA and protein expression of pro-inflammatory cytokines (Interleukin-1β/6, and tumor necrosis factor-α) were measured by real-time RT-PCR and ELISA, respectively; NF-κB p65 expression was determined by western blotting. Madecassoside significantly reduced brain infarct area, resolved neurological deficit, and ameliorated neuronal apoptosis. It also significantly reduced the levels of malondialdehyde and nitric oxide, and augmented the antioxidant activity in rats subjected to cerebral I/R. Moreover, the levels of pro-inflammatory cytokines and NF-κB p65 significantly reduced after Madecassoside treatment.
    These results indicate that Madecassoside is neuroprotective and may be useful in reducing the damage caused by stroke.
    Planta Med. 2008 Jun;74(8):809-15.
    Madecassoside isolated from Centella asiatica herbs facilitates burn wound healing in mice.[Pubmed: 18484522 ]
    The current study was designed to investigate the effect of Madecassoside, the major triterpene in CENTELLA ASIATICA, on burn wound healing and its possible mechanism of action.
    An oral administration of Madecassoside (6, 12, 24 mg/kg) facilitated wound closure in a time-dependent manner and reached its peak effect, nearly completely wound closure, on day 20 in the group receiving the highest dose of 24 mg/kg of Madecassoside. Further histopathological analysis revealed that Madecassoside alleviated infiltration of inflammatory cells as well as enhanced epithelisation resulting from dermal proliferation of fibroblasts. Madecassoside at higher doses (12 and 24 mg/kg) decreased nitric oxide (NO) levels and malondialdehyde (MDA) content in the burn skin tissue. However, reduced glutathione (GSH) and hydroxyproline levels were increased in the same skin tissue. In addition, Madecassoside promoted skin angiogenesis IN VIVO, correlating with our findings IN VITRO that it stimulated endothelial cell growth in a rat aortic ring assay. These data suggest that Madecassoside has significant wound-healing activity and is one of the major reasons for the use of C. ASIATICA herbs in the successful treatment of burn injury.
    Moreover, the results from the present study indicate that the effect of Madecassoside on wound healing may involve several mechanisms including antioxidative activity, collagen synthesis and angiogenesis.
    Madecassoside Description
    Source: The herbs of Centella asiatica (L.) Urban
    Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds
    Poricoic acid G

    Catalog No: CFN95056
    CAS No: 415724-84-4
    Price: $318/5mg

    Catalog No: CFN95047
    CAS No: 35589-22-1
    Price: $413/5mg

    Catalog No: CFN90458
    CAS No: 66791-77-3
    Price: $288/20mg

    Catalog No: CFN95095
    CAS No: 87686-87-1
    Price: $218/10mg
    Chrysin 6-C-glucoside 8-C-arabinos...

    Catalog No: CFN92285
    CAS No: 185145-34-0
    Price: $368/5mg
    Ganoderic acid H

    Catalog No: CFN92056
    CAS No: 98665-19-1
    Price: $399/5mg
    Sagittatoside B

    Catalog No: CFN90211
    CAS No: 118525-36-3
    Price: $318/5mg

    Catalog No: CFN96098
    CAS No: 87562-14-9
    Price: $333/5mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.

    PMID: 30417089
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 1.0255 mL 5.1275 mL 10.255 mL 20.5101 mL 25.6376 mL
    5 mM 0.2051 mL 1.0255 mL 2.051 mL 4.102 mL 5.1275 mL
    10 mM 0.1026 mL 0.5128 mL 1.0255 mL 2.051 mL 2.5638 mL
    50 mM 0.0205 mL 0.1026 mL 0.2051 mL 0.4102 mL 0.5128 mL
    100 mM 0.0103 mL 0.0513 mL 0.1026 mL 0.2051 mL 0.2564 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Kinase Assay:
    Toxicol In Vitro. 2011 Jun;25(4):890-6.
    In vitro inhibitory effects of asiaticoside and madecassoside on human cytochrome P450.[Pubmed: 21349323 ]
    The inhibitory effects and types of inhibition of asiaticoside and Madecassoside on human CYPs were studied in vitro using recombinant human CYPs.
    The median inhibitory concentrations (IC50) of asiaticoside and Madecassoside were determined for CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4. Asiaticoside inhibited CYP2C19 (IC50 = 412.68 ± 15.44 μM) and CYP3A4 (IC50=343.35 ± 29.35 μM). Madecassoside also inhibited CYP2C19 (IC50 = 539.04 ± 14.18 μM) and CYP3A4 (IC50 = 453.32 ± 39.33 μM). Asiaticoside and Madecassoside had no effect on the activities of CYP1A2, CYP2C9 and CYP2D6 and CYP2E1. Assessment of mechanism-based inhibition and the type of inhibition were performed for asiaticoside and Madecassoside with CYP2C19 and CYP3A4. These results suggested that Madecassoside is a mechanism-based inhibitor of CYP2C19 and CYP3A4. Assessment of mechanism-based inhibition by asiaticoside was limited by its low solubility. Asiaticoside exhibited non-competitive inhibition of CYP2C19 (Ki=385.24 ± 8.75 μM) and CYP3A4 (Ki = 535.93 ± 18.99 μM). Madecassoside also showed non-competitive inhibition of CYP2C19 (Ki = 109.62 ± 6.14 μM) and CYP3A4 (Ki = 456.84 ± 16.43 μM).
    These results suggest that asiaticoside and Madecassoside could cause drug-drug interactions via inhibition of CYP2C19 and CYP3A4. An in vivo study is needed to examine this further.
    Cell Research:
    Int Immunopharmacol. 2010 Jul;10(7):723-9.
    Madecassoside suppresses LPS-induced TNF-alpha production in cardiomyocytes through inhibition of ERK, p38, and NF-kappaB activity.[Pubmed: 20381648 ]
    Madecassoside (MA) is a major triterpenoid component of Centella asiatica that has a wide range of biological activities, including wound-healing and antioxidative activities.
    In the present study, we evaluated the therapeutic effect of MA on rat cardiac dysfunction during sepsis induced by lipopolysaccharide (LPS), as well as the possible mechanism. Pretreatment of the neonatal rat cardiomyocytes with MA inhibited LPS-induced TNF-alpha production in a concentration-dependent manner. In addition, pretreatment of the rats with MA (20 mg/kg, i.g.) significantly inhibited the elevation of plasma TNF-alpha, delayed the fall of mean arterial blood pressure, and attenuated the tachycardia induced by LPS. We further observed that MA prevented the LPS-induced nuclear factor-kappa B (NF-kappaB) translocation from the cytoplasm into the nucleus, and inhibited the LPS-induced phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) and p38.
    These results suggest that MA inhibits LPS-stimulated TNF-alpha production through the blocking of ERK1/2, p38 and NF-kappaB pathways in cardiomyocytes. MA may have cardioprotective effects in LPS-mediated sepsis.
    Animal Research:
    Pharmacol Biochem Behav. 2014 Sep;124:434-42.
    Protective effect of madecassoside against cognitive impairment induced by D-galactose in mice.[Pubmed: 25106808]
    This study was designed to investigate the protective effect of Madecassoside from Hydrocotyle sibthorpioides against cognitive impairment induced by D-galactose (D-gal) in mice.
    The result revealed that treatment with Madecassoside significantly reversed D-gal-induced learning and memory impairments, as measured by the Morris water-maze test. Studies on the potential mechanisms of this action showed that Madecassoside significantly reduced oxidative stress and suppress inflammatory responses via blocking NF-κB and ERK/p38 MAPK pathways. Moreover, Madecassoside markedly attenuated the content and deposition of β-amyloid peptide by inducing a decrease in the expression of amyloid protein precursor, β-site amyloid cleaving enzyme-1 and cathepsin B and an increase in the levels of neprilysin and insulin-degrading enzyme. Madecassoside significantly increased the expression of synapse plasticity-related proteins in the hippocampus, such as postsynaptic density 95, long-term potentiation, N-methyl-D-aspartic acid receptors, Ca(2+)/calmodulin-dependent protein kinase II, NMDA receptor subunit 1, protein kinase C, protein kinase A, cAMP-response element binding protein, and brain-derived neurotrophic factor. In addition, Madecassoside significantly increased the levels of acetylcholine but decreased cholinesterase activity.
    In conclusion, the protective effect of Madecassoside against d-gal-induced cognitive impairment was mainly due to its ability to reduce oxidative damage, improve synaptic plasticity and restore cholinergic function. These findings suggest that Madecassoside can be considered as a potential agent for preventing cognitive impairment.
    Biol Pharm Bull. 2008 Mar;31(3):458-63.
    Madecassoside reduces ischemia-reperfusion injury on regional ischemia induced heart infarction in rat.[Pubmed: 18310910]
    Madecassoside (MA), one of the principle terpenoids in Centella asiatica, has shown protect effect on isolated rat hearts and isolated cardiomyocytes against reperfusion injury in our previous studies. The aim of this study is to investigate if MA also protected against myocardial ischemia-reperfusion injury in vivo.
    The ischemia infarction model was established in rats. Left ventricular function was monitored during the ischemia-reperfusion period by a multi-channel recorder. After the ischemia-reperfusion process the infarcted areas were assessed. The levels of lactate dehydrogenase (LDH), creatinephosphokinase (CK), malondialdehyde (MDA), super-oxide dismutase (SOD) and C-reactive protein (CRP) in serum were determined. Cardiomyocytic apoptosis was measured by terminal-deoxynucleotidyl transferase mediated nick end labeling (TUNEL) staining. Pre-treatment with MA (50, 10 mg/kg) attenuated myocardial damage characteristic of decreasing infarct size, decreasing LDH and CK release. Activities of SOD were increased and MDA level increased obviously in control group whereas pretreatment with MA blunted the decrease of SOD activity, markedly reduced the level of MDA and the activity of CRP, and relieved myocardial cell apoptosis.
    These results suggest that MA has the protective effect on myocardial ischemia-reperfusion injury. This protection ability possibly due to its anti-lipid peroxidation, anti-inflammation and anti-apoptosis function and the enhancement of SOD activity.